Singh Biotechnology

Executive Summary

Singh Biotechnology is a private, US-based biotech company pioneering novel therapeutics for cancers, autoimmune, and ophthalmologic diseases using its proprietary single-domain antibody (sdAb) platform. Founded in 2008, the company leverages miniature antibodies capable of targeting intracellular proteins, addressing previously undruggable targets. Its lead candidate, SBT-100, has received FDA orphan drug designations for pancreatic cancer and osteosarcoma, highlighting its potential in high unmet need indications. The platform's versatility also positions Singh to expand into other therapeutic areas, including autoimmune and ophthalmologic diseases, through its pipeline of preclinical candidates. Despite being in early stages, the company's innovative approach and orphan designations provide a foundation for upcoming value-inflection points. Singh's progress is closely watched by investors seeking exposure to novel biologic platforms with multiple shots on goal.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 trial initiation for SBT-100 in pancreatic cancer75% success
• Q3 2026FDA Fast Track designation for SBT-100 in osteosarcoma80% success
• TBDPreclinical proof-of-concept data for autoimmune sdAb candidate50% success